Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reblozyl

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

Acceleron rockets on positive mid-stage pulmonary arterial hypertension data

Sotatercept hit primary and all secondary endpoints

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

- PMLiVE

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Late-stage candidate hit the mark in phase 3 study

Bristol Myers Squibb logo

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

Could win approval in group of rare blood cancers

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

Von der Leyen elected new European Commission president

Pledges green deal and universal healthcare for 500m citizens

- PMLiVE

Celgene files luspatercept ahead of key merger vote

Analysts predict peak revenues of $2bn

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

Joined-up thinking on anaemia

Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated.

Dovetail

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links